FTC requests additional info from Boston Scientific and BTG ahead of $4.2B merger

The antitrust regulator wants documentation related to the companies’ therapeutic beads businesses, which form the bulk of BTG’s interventional oncology offerings. (Wikimedia Commons)

The Federal Trade Commission is requesting additional information from Boston Scientific and BTG ahead of their proposed $4.2 billion acquisition deal.

The antitrust regulator is seeking additional documentation related to the companies’ therapeutic beads businesses—which form the bulk of BTG’s interventional oncology offerings, and which Boston Scientific has eyed as the means to help transform its cancer franchise, from one primarily offering delivery tools into a $500 million enterprise.

BTG’s TheraSphere Y-90 radiotherapy for liver cancer, for example, consists of implantable glass microspheres that deliver high doses of localized radiation. It’s currently in early-stage development for lung and breast cancers, as well as bone metastases.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The London-based medtech company also offers its LC Bead line of hydrogel microspheres, which are used to block the flow of blood and starve growing hypervascular tumors and arteriovenous malformations, as well as a chemotherapy-eluting bead system.

RELATED: Boston Scientific makes $4.2B offer to buy BTG and build out its oncology, vascular franchises

Following its announcement last November, analysts at Jeffries described BTG's interventional medicine and oncology portfolios as the "hidden gem" in the deal—and that it could be as transformative as Boston Scientific’s 2015 acquisition of AMS, which helped the medtech giant enter the men’s health and urology sectors.

In addition, more than 90% of BTG’s current revenue comes from the U.S., which Boston Scientific sees as an opportunity to pull new products up through its global marketing and commercialization teams and into new markets.

RELATED: The top 10 medtech companies of 2024 | Boston Scientific

In a statement, Boston Scientific and BTG said they plan to cooperate with the FTC’s request as soon as possible, and believe they are still on track with their previous timeline for the closure of the deal, expected by mid-2019. They also noted the planned merger has already received sign-offs from regulatory authorities in Germany and Taiwan.

And while the transaction has been unanimously approved by the boards of directors of both companies, the deal is still subject to a vote of BTG’s shareholders, scheduled for Feb. 28. BTG’s three largest shareholders, covering about a third of the company’s outstanding shares, have already committed to vote in favor of the deal.

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.